Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms
Akin Akinc,William Querbes,Soma De,June Qin,Maria Frank-Kamenetsky,K. Narayanannair Jayaprakash,Muthusamy Jayaraman,Kallanthottathil G Rajeev,William L Cantley,J Robert Dorkin,James S Butler,LiuLiang Qin,Timothy Racie,Andrew Sprague,Eugenio Fava,Anja Zeigerer,Michael J Hope,Marino Zerial,Dinah WY Sah,Kevin Fitzgerald,Mark A Tracy,Muthiah Manoharan,Victor Koteliansky,Antonin de Fougerolles,Martin A Maier
DOI: https://doi.org/10.1038/mt.2010.85
IF: 12.91
2010-07-01
Molecular Therapy
Abstract:Lipid nanoparticles (LNPs) have proven to be highly efficient carriers of short-interfering RNAs (siRNAs) to hepatocytes in vivo; however, the precise mechanism by which this efficient delivery occurs has yet to be elucidated. We found that apolipoprotein E (apoE), which plays a major role in the clearance and hepatocellular uptake of physiological lipoproteins, also acts as an endogenous targeting ligand for ionizable LNPs (iLNPs), but not cationic LNPs (cLNPs). The role of apoE was investigated using both in vitro studies employing recombinant apoE and in vivo studies in wild-type and apoE(-/-) mice. Receptor dependence was explored in vitro and in vivo using low-density lipoprotein receptor (LDLR(-/-))-deficient mice. As an alternative to endogenous apoE-based targeting, we developed a targeting approach using an exogenous ligand containing a multivalent N-acetylgalactosamine (GalNAc)-cluster, which binds with high affinity to the asialoglycoprotein receptor (ASGPR) expressed on hepatocytes. Both apoE-based endogenous and GalNAc-based exogenous targeting appear to be highly effective strategies for the delivery of iLNPs to liver.
genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology